Trial Profile
A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipafricept (Primary)
- Indications Fibroma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors OncoMed Pharmaceuticals
- 27 Sep 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 14 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.